drugset / Trial / NCT01282073
Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy
Phase 3
Completed
43 enrolled
Kyungpook National University Hospital
Hanmi Pharmaceutical Company Limited · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
Cyclosporin decreases proteinuria and improve renal function in patients with idiopathic membranous nephropathy, but has a risk of side effects such as nephrotoxicity. The investigators plan to the study to evaluate whether mycophenolate mofetil (MMF) could be a reasonable alternative with fewer side effect.
Timeline
- Start
- 2011-03
- Primary completion
- 2016-05
- Completion
- 2016-05
Publications
- von Groote TC, Williams G, Au EH, Chen Y, Mathew AT, Hodson EM, Tunnicliffe DJ. Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2021 Nov 15;11(11):CD004293. doi: 10.1002/14651858.CD004293.pub4.
- Choi JY, Kim DK, Kim YW, Yoo TH, Lee JP, Chung HC, Cho KH, An WS, Lee DH, Jung HY, Cho JH, Kim CD, Kim YL, Park SH. The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. J Korean Med Sci. 2018 Feb 26;33(9):e74. doi: 10.3346/jkms.2018.33.e74.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 4 mg/kg | — |
| Subject | Mycophenolate Mofetil | Small molecule | 500 mg | — |
| Subject | Mycophenolate Mofetil | Small molecule | 750 mg | — |
| Subject | Mycophenolate Mofetil | Small molecule | 1000 mg | — |
| Comparator | Deflazacort | Other / unclassified | — | — |
| Comparator | Methylprednisone | Unknown | — | — |
| Comparator | Prednisolone | Other / unclassified | 0.15 mg/kg | — |
| Comparator | Prednisolone | Other / unclassified | — | — |